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The UK has a world leading reputation for clinical
research. However this position is being undermined by
an overly complex regulatory and governance environ-
ment that has had a very negative effect on undertaking
clinical trials in an efficient way. The European Clinical
Trials Directive (EUCTD) was implemented into UK law
in May 2004 and was intended to provide greater protec-
tion to patients and volunteers participating in clinical
trials and increase the quality of trial conduct. At the same
time the Research Governance Framework (RGF) was
introduced into the NHS. Increasingly the research com-
munity has viewed implementation of both the EUCTD
and RGF as being disproportionate and ‘gold plated’.
In 2010 the Academy of Medical Sciences was invited
by Government to review the regulation and governance
of health research and make recommendations to
improve current processes. Despite recent attempts to
improve parts of the regulation pathway, the review iden-
tified that significant challenges remain, including: delays
and duplication in obtaining NHS research permissions;
a lack of proportionality in the regulation of clinical trials;
and a healthcare culture that fails to fully support the
value and benefits of health research. The Academy’s
report recommended the creation of a new health regula-
tor to rationalise the regulation and governance of health
research; steps to streamline the approval of research stu-
dies by NHS Trusts; and changes to improve the UK
environment for clinical trials.
Since the publication of the Academy’sr e p o r tan u m -
ber of positive changes have been made. The 2011 Plan
for Growth outlined a package of government measures
to foster growth in the healthcare and life sciences and
took forward a number of recommendations from the
Academy report, including establishment of a new
Health Research Authority to streamline regulation and
improve the cost effectiveness of clinical trials, and mak-
ing future funding by the National Institute for Health
Research to NHS Trusts conditional on meeting bench-
marks. The Government has created a new duty for
clinical commissioning groups to promote research
innovation and for the NHS Commissioning Board to
ensure provision of treatment costs for patients who are
taking part in research. The MHRA are introducing a
risk based approach to management of clinical trials
based on the marketing status of an investigational med-
icinal produce and the standard medical care that would
facilitate a proportionate approach to trial activities. The
ongoing review of the EUCTD may offer a further
opportunity to reduce the regulatory burden on aca-
demic trials.
The above changes are welcome and should result in
reductions in the time to obtain approvals and permis-
sions for clinical trials and some reduction in trial man-
agement costs. However it remains to be seen whether
the health research regulatory agency will have sufficient
authority to achieve more efficient working between reg-
ulators, researchers and the NHS to maintain the UKs
historical position as a world leader in designing and
delivering high quality clinical trials.
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